BEIJING/BEIJING, June 30 (Reuters) – China’s Hybio Pharmaceutical said the U.S. Food and Drug Administration has accepted for reviews its abbreviated new drug applications for a generic tirzepatide injection, a stock exchange filing showed on Tuesday.
(Reporting by Xiuhao Chen, Yukun Zhang and Andrew Silver; Editing by Joe Bavier)
